1
|
Mao QD, Zhang W, Zhao K, Cao B, Yuan H, Wei LZ, Song MQ, Liu XS. MicroRNA-455 suppresses the oncogenic function of HDAC2 in human colorectal cancer. ACTA ACUST UNITED AC 2017; 50:e6103. [PMID: 28538837 PMCID: PMC5479389 DOI: 10.1590/1414-431x20176103] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2017] [Accepted: 04/05/2017] [Indexed: 12/22/2022]
Abstract
Colorectal cancer (CRC) is the fourth leading cause of cancer-induced mortality. Histone deacetylase 2 (HDAC2) is involved in prognosis and therapy of CRC. This study aimed to explore novel therapeutic targets for CRC. The alteration of HDAC2 expression in CRC tissues was estimated by qRT-PCR. After lentivirus transfection, HDAC2 knockdown was confirmed by western blot analysis. The effect of HDAC2 knockdown on cell proliferation was then assessed by 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. Screened by TargetScan, microRNA (miR)-455 was predicted to bind to 3′UTR of HDAC2 and the prediction was verified by luciferase assay. Finally, cells were transfected, respectively, with miR-455 mimics or miR-455 negative control (miR-NC) and the expression of HDAC2, cell proliferation and apoptosis of transfected cells were respectively evaluated by western blot analysis, MTT assay and flow cytometry. Results showed that the HDAC2 expression was up-regulated in CRC tissues (P<0.05). HDAC2 knockdown significantly decreased cell viability at day 3 (P<0.05), day 4 (P<0.01), and day 5 (P<0.001) after infection. Then, miR-455 was verified to directly target HDAC2, resulting in a significant difference in luciferase activity (P<0.01). Moreover, miR-455 decreased the expression of HDAC2 (P<0.01). miR-455 remarkably decreased cell viability at day 3 (P<0.05), day 4 (P<0.01), and day 5 (P<0.001) after transfection while inducing cell apoptosis (P<0.001). In conclusion, miR-455 inhibited cell proliferation while inducing cell apoptosis by targeting HDAC2 in CRC cells.
Collapse
Affiliation(s)
- Q D Mao
- Department of Gastroenterology, Huangdao Division, The Affiliated Hospital of Qingdao University, Qingdao, China
| | - W Zhang
- Department of Gastroenterology, Huangdao Division, The Affiliated Hospital of Qingdao University, Qingdao, China
| | - K Zhao
- Department of Gastroenterology, Huangdao Division, The Affiliated Hospital of Qingdao University, Qingdao, China
| | - B Cao
- Department of Gastroenterology, Huangdao Division, The Affiliated Hospital of Qingdao University, Qingdao, China
| | - H Yuan
- Department of Gastroenterology, Huangdao Division, The Affiliated Hospital of Qingdao University, Qingdao, China
| | - L Z Wei
- Department of Gastroenterology, Huangdao Division, The Affiliated Hospital of Qingdao University, Qingdao, China
| | - M Q Song
- Department of Gastroenterology, Huangdao Division, The Affiliated Hospital of Qingdao University, Qingdao, China
| | - X S Liu
- Department of Gastroenterology, Laoshan Division, The Affiliated Hospital of Qingdao University, Qingdao, China
| |
Collapse
|
2
|
Kwun J, Oh BC, Gibby AC, Ruhil R, Lu VT, Kim DW, Page EK, Bulut OP, Song MQ, Farris AB, Kirk AD, Knechtle SJ, Iwakoshi NN. Patterns of de novo allo B cells and antibody formation in chronic cardiac allograft rejection after alemtuzumab treatment. Am J Transplant 2012; 12:2641-51. [PMID: 22759336 PMCID: PMC5464351 DOI: 10.1111/j.1600-6143.2012.04181.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Even though the etiology of chronic rejection (CR) is multifactorial, donor specific antibody (DSA) is considered to have a causal effect on CR development. Currently the antibody-mediated mechanisms during CR are poorly understood due to lack of proper animal models and tools. In a clinical setting, we previously demonstrated that induction therapy by lymphocyte depletion, using alemtuzumab (anti-human CD52), is associated with an increased incidence of serum alloantibody, C4d deposition and antibody-mediated rejection in human patients. In this study, the effects of T cell depletion in the development of antibody-mediated rejection were examined using human CD52 transgenic (CD52Tg) mice treated with alemtuzumab. Fully mismatched cardiac allografts were transplanted into alemtuzumab treated CD52Tg mice and showed no acute rejection while untreated recipients acutely rejected their grafts. However, approximately half of long-term recipients showed increased degree of vasculopathy, fibrosis and perivascular C3d depositions at posttransplant day 100. The development of CR correlated with DSA and C3d deposition in the graft. Using novel tracking tools to monitor donor-specific B cells, alloreactive B cells were shown to increase in accordance with DSA detection. The current animal model could provide a means of testing strategies to understand mechanisms and developing therapeutic approaches to prevent chronic rejection.
Collapse
Affiliation(s)
- J. Kwun
- Emory Transplant Center, Department of Surgery, Emory University School of Medicine, Atlanta, GA
| | - B. C. Oh
- Emory Transplant Center, Department of Surgery, Emory University School of Medicine, Atlanta, GA
| | - A. C. Gibby
- Emory Transplant Center, Department of Surgery, Emory University School of Medicine, Atlanta, GA
| | - R. Ruhil
- Emory Transplant Center, Department of Surgery, Emory University School of Medicine, Atlanta, GA
| | - V. T. Lu
- Emory Transplant Center, Department of Surgery, Emory University School of Medicine, Atlanta, GA
| | - D. W. Kim
- Emory Transplant Center, Department of Surgery, Emory University School of Medicine, Atlanta, GA
| | - E. K. Page
- Emory Transplant Center, Department of Surgery, Emory University School of Medicine, Atlanta, GA
| | - O. P. Bulut
- Emory Transplant Center, Department of Surgery, Emory University School of Medicine, Atlanta, GA
| | - M. Q. Song
- Emory Transplant Center, Department of Surgery, Emory University School of Medicine, Atlanta, GA
| | - A. B. Farris
- Department of Pathology, Emory University School of Medicine, Atlanta, GA
| | - A. D. Kirk
- Emory Transplant Center, Department of Surgery, Emory University School of Medicine, Atlanta, GA
| | - S. J. Knechtle
- Emory Transplant Center, Department of Surgery, Emory University School of Medicine, Atlanta, GA,Corresponding author: Stuart J. Knechtle,
| | - N. N. Iwakoshi
- Emory Transplant Center, Department of Surgery, Emory University School of Medicine, Atlanta, GA
| |
Collapse
|